Correction: Cost-effectiveness analysis of cabozantinib plus atezolizumab for advanced hepatocellular carcinoma

Podobne knjige/članki

• Correction: Cost-effectiveness analysis of cabozantinib plus atezolizumab for advanced hepatocellular carcinoma
  od: Yan Zhu, et al.
  Izdano: (2025-11-01)
• Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis
  od: Alessandro Rizzo, et al.
  Izdano: (2023-01-01)
• Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China
  od: Hongyu Gong, et al.
  Izdano: (2023-03-01)
• Cost-effectiveness analysis of atezolizumab plus bevacizumab versus sorafenib in first line treatment for Chinese subpopulation with unresectable hepatocellular carcinoma
  od: Chien-Yu Tseng, et al.
  Izdano: (2023-11-01)
• Cabozantinib plus atezolizumab in previously untreated advanced hepatocellular carcinoma and previously treated gastric cancer and gastroesophageal junction adenocarcinoma: results from two expansion cohorts of a multicentre, open-label, phase 1b trial (COSMIC-021)Research in context
  od: Daneng Li, et al.
  Izdano: (2024-01-01)